FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2471493685> ?p ?o ?g. }

• W2471493685 endingPage "22" @default.
• W2471493685 startingPage "11" @default.
• W2471493685 abstract "The heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of pathological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time of surgery).We used adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibitor neratinib with control. Eligible women were categorized according to eight biomarker subtypes on the basis of human epidermal growth factor receptor 2 (HER2) status, hormone-receptor status, and risk according to a 70-gene profile. Neratinib was evaluated against control with regard to 10 biomarker signatures (prospectively defined combinations of subtypes). The primary end point was pathological complete response. Volume changes on serial magnetic resonance imaging were used to assess the likelihood of such a response in each patient. Adaptive assignment to experimental groups within each disease subtype was based on Bayesian probabilities of the superiority of the treatment over control. Enrollment in the experimental group was stopped when the 85% Bayesian predictive probability of success in a confirmatory phase 3 trial of neoadjuvant therapy reached a prespecified threshold for any biomarker signature (graduation). Enrollment was stopped for futility if the probability fell to below 10% for every biomarker signature.Neratinib reached the prespecified efficacy threshold with regard to the HER2-positive, hormone-receptor-negative signature. Among patients with HER2-positive, hormone-receptor-negative cancer, the mean estimated rate of pathological complete response was 56% (95% Bayesian probability interval [PI], 37 to 73%) among 115 patients in the neratinib group, as compared with 33% among 78 controls (95% PI, 11 to 54%). The final predictive probability of success in phase 3 testing was 79%.Neratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer. (Funded by QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.)." @default.
• W2471493685 created "2016-07-22" @default.
• W2471493685 creator A5000761973 @default.
• W2471493685 creator A5001315712 @default.
• W2471493685 creator A5002836828 @default.
• W2471493685 creator A5003921604 @default.
• W2471493685 creator A5005007467 @default.
• W2471493685 creator A5005537242 @default.
• W2471493685 creator A5009930268 @default.
• W2471493685 creator A5012471769 @default.
• W2471493685 creator A5013631740 @default.
• W2471493685 creator A5013766852 @default.
• W2471493685 creator A5014135109 @default.
• W2471493685 creator A5015224704 @default.
• W2471493685 creator A5021113979 @default.
• W2471493685 creator A5027858713 @default.
• W2471493685 creator A5028067020 @default.
• W2471493685 creator A5029076260 @default.
• W2471493685 creator A5030715622 @default.
• W2471493685 creator A5031366322 @default.
• W2471493685 creator A5033544737 @default.
• W2471493685 creator A5034713910 @default.
• W2471493685 creator A5034796205 @default.
• W2471493685 creator A5038881654 @default.
• W2471493685 creator A5042271475 @default.
• W2471493685 creator A5044499466 @default.
• W2471493685 creator A5046842846 @default.
• W2471493685 creator A5048646563 @default.
• W2471493685 creator A5050253207 @default.
• W2471493685 creator A5051494466 @default.
• W2471493685 creator A5053577410 @default.
• W2471493685 creator A5057008789 @default.
• W2471493685 creator A5059538753 @default.
• W2471493685 creator A5062190609 @default.
• W2471493685 creator A5065945123 @default.
• W2471493685 creator A5068347637 @default.
• W2471493685 creator A5071176191 @default.
• W2471493685 creator A5071749616 @default.
• W2471493685 creator A5072789687 @default.
• W2471493685 creator A5073571977 @default.
• W2471493685 creator A5074841861 @default.
• W2471493685 creator A5076178845 @default.
• W2471493685 creator A5078449638 @default.
• W2471493685 creator A5090318660 @default.
• W2471493685 creator A5091848952 @default.
• W2471493685 date "2016-07-07" @default.
• W2471493685 modified "2023-10-18" @default.
• W2471493685 title "Adaptive Randomization of Neratinib in Early Breast Cancer" @default.
• W2471493685 cites W1751006537 @default.
• W2471493685 cites W1987576644 @default.
• W2471493685 cites W1993702531 @default.
• W2471493685 cites W2005494948 @default.
• W2471493685 cites W2016884538 @default.
• W2471493685 cites W2020887996 @default.
• W2471493685 cites W2024484688 @default.
• W2471493685 cites W2075894019 @default.
• W2471493685 cites W2094615848 @default.
• W2471493685 cites W2094793616 @default.
• W2471493685 cites W2095861620 @default.
• W2471493685 cites W2096145980 @default.
• W2471493685 cites W2099152441 @default.
• W2471493685 cites W2100396735 @default.
• W2471493685 cites W2111578514 @default.
• W2471493685 cites W2113762115 @default.
• W2471493685 cites W2115961074 @default.
• W2471493685 cites W2119549339 @default.
• W2471493685 cites W2123591186 @default.
• W2471493685 cites W2129060478 @default.
• W2471493685 cites W2131051049 @default.
• W2471493685 cites W2132894311 @default.
• W2471493685 cites W2154976095 @default.
• W2471493685 cites W2168372454 @default.
• W2471493685 cites W2316247073 @default.
• W2471493685 cites W2474664935 @default.
• W2471493685 cites W2916315386 @default.
• W2471493685 doi "https://doi.org/10.1056/nejmoa1513750" @default.
• W2471493685 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5259558" @default.
• W2471493685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27797314" @default.
• W2471493685 hasPublicationYear "2016" @default.
• W2471493685 type Work @default.
• W2471493685 sameAs 2471493685 @default.
• W2471493685 citedByCount "273" @default.
• W2471493685 countsByYear W24714936852016 @default.
• W2471493685 countsByYear W24714936852017 @default.
• W2471493685 countsByYear W24714936852018 @default.
• W2471493685 countsByYear W24714936852019 @default.
• W2471493685 countsByYear W24714936852020 @default.
• W2471493685 countsByYear W24714936852021 @default.
• W2471493685 countsByYear W24714936852022 @default.
• W2471493685 countsByYear W24714936852023 @default.
• W2471493685 crossrefType "journal-article" @default.
• W2471493685 hasAuthorship W2471493685A5000761973 @default.
• W2471493685 hasAuthorship W2471493685A5001315712 @default.
• W2471493685 hasAuthorship W2471493685A5002836828 @default.
• W2471493685 hasAuthorship W2471493685A5003921604 @default.
• W2471493685 hasAuthorship W2471493685A5005007467 @default.
• W2471493685 hasAuthorship W2471493685A5005537242 @default.
• W2471493685 hasAuthorship W2471493685A5009930268 @default.

• next